All IndicationsPhase 3Phase 3Phase 3Phase 2
Pain
4
Companies
5
Drug Programs
3
Phase 3
0
Upcoming PDUFAs
Competitors
VRTX
Vertex Pharmaceuticals Incorporated
Suzetrigine
JNJ
Johnson & Johnson
Acetaminophen/Naproxen Sodium Fixed Combination
JAZZ
Jazz Pharmaceuticals plc
Nabiximols
JNJ
Johnson & Johnson
tapentadol HCl
LTGO
Latigo Biotherapeutics
Journavx
| Company | Drug | Phase | Designations | Timeline | Trial ID |
|---|---|---|---|---|---|
| VRTX Vertex Pharmaceuticals Incorporated | Suzetrigine | Phase 3 | — | — | — |
| JNJ Johnson & Johnson | Acetaminophen/Naproxen Sodium Fixed Combination | Phase 3 | — | — | — |
| JAZZ Jazz Pharmaceuticals plc | Nabiximols | Phase 3 | — | — | — |
| JNJ Johnson & Johnson | tapentadol HCl | Phase 2 | — | — | — |
| LTGO Latigo Biotherapeutics | Journavx | — | — | — | — |
Development Stage Distribution
Unknown
1
Phase 3
3
Phase 2
1
PDUFA Timeline
No upcoming PDUFA dates for this indication.
Not financial advice
Signals are probabilistic and based on historical data — past performance doesn't guarantee future results. Do your own research.